Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response

Background: Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive /HER2-negative breast cancer (ER+/HER2- BC) allows real-time evaluation of treatment sensitivity by monitoring tumour response and offers the opportunity of personalised therapy. However, the lack of reproducible biomarke...

Full description

Saved in:
Bibliographic Details
Main Authors: Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, Maria M. Caffarel, Ander Urruticoechea
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Translational Oncology
Subjects:
Neoadjuvant endocrine therapy
Aromatase inhibitors
ER+/HER2- breast cancer
PAM50
Normal-like subtype
ROR
Online Access:http://www.sciencedirect.com/science/article/pii/S193652332500138X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S193652332500138X

Similar Items